The Anti-SARS-CoV-2 IgM (S1 RBD) ELISA is for the detection of IgM antibodies directed against SARS-CoV-2-S1 RBD in human blood. The Anti-SARS-CoV-2 IgM (S1 RBD) ELISA is intended for research use only and not for use in diagnostic or clinical procedures.


The Anti-SARS-CoV-2 IgM (S1 RBD) ELISA is for Research Use Only and not for use in diagnostic procedures

Size: 1×96 wells
Incubation Time: 2 hours 40 minutes
Sample Type: Serum and Plasma
Sample Size: 100 µl

Assay is manufactured in Germany by Mediagnost
Controls Included

Assay Principle

The Anti-SARS-CoV-2 IgM ELISA is a two-step enzyme-linked immunosorbent assay. Wells of a 96-well microtiter plate are coated with recombinant SARS-CoV-2-S1 Receptor Binding Domain (RBD). After addition of human serum or plasma samples anti-S1 IgM antibodies from the sample bind to the immobilized antigen during a two hours incubation followed by several washing steps in order to remove unbound components. The bound anti-SARS-CoV-2 IgM antibodies are detected by incubation with horseradish peroxidase (HRP)-conjugated anti-human IgM for 30 minutes. Subsequently, a HRP substrate solution containing 3,3’,5,5’-Tetramethylbenzidine (TMB) is added resulting in the formation of a blue colour. The reaction is terminated by the addition of 0.2 M H2SO4 changing the blue colour into yellow signals which are measured by an absorbance microtiter plate reader at 450 nm. The extinction increases with the amount of the captured antibodies directed against SARS-CoV-2-S1 (RBD) from the patient’s sera.

Related Products

Anti-SARS-CoV-2 IgA (S1 RBD) ELISA Assay
Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay

Additional Information

Assay Background

In December 2019 a novel coronavirus SARS-CoV-2 was identified in Wuhan, China and was announced as the causative agent for COVID-19 disease. The incubation period of the disease is 2-14 days. Symptoms of COVID-19 include i.a. fever, fatigue and cough, shortness of breath, muscle pain and tiredness. Most patients have a good prognosis; some severe cases may develop pneumonia, have severe acute shortness of breath, or even succumb to the disease.
The entry process of SARS-CoV-2 to the host cell is mediated by the envelope-embedded surface-located spike glycoprotein S. The protein is cleaved by host proteases into the S1 and S2 subunits, which are responsible for receptor recognition and membrane fusion, respectively1.
As target antigen of the assay the recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 S1 spike protein, which binds the ACE2 receptor, is used. The use of RBD increases the specificity of the assay since the domain is identical with SARS-CoV but not with MERS-CoV for example. Antibodies directed against the RBD neutralize both virus strains SARS-CoV and SARS-CoV-22.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations